Clinical trial

Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

NCT06544577

StatusUNKNOWN

Study typeOBSERVATIONAL

Start date2024-07-13

PhaseN/A

Study timeline

Study start (actual)2024-07-13Date precision: day

Registry last updated2024-08-09

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

ESR1 Gene Mutationunresolved

Advanced Breast Cancerunresolved

Safetyunresolved

Interventions

ELacestrantDRUG · verified · RxNorm: elacestrant

Sponsors & collaborators

SciClone Pharmaceuticalslead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06544577 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.